 |
|
Abnormal immune cells may cause unprovoked anaphylaxis
November 12, 2007Two new clinical reports shed light on why some people suffer from recurrent episodes of idiopathic anaphylaxis--a potentially life-threatening condition of unknown cause characterized by a drop in blood pressure, fainting episodes, difficulty in breathing, and wheezing.
In some of these individuals, researchers have found mast cells (a type of immune cell involved in allergic reactions) that have a mutated cell surface receptor that disturbs normal processes within the cell. Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), say the association of this mutation with unprovoked anaphylaxis is striking. The hope is that these individuals may respond to inhibitors targeting the mutated cell surface receptor.
While some people suffer anaphylaxis as part of a serious allergic reaction, in two out of three people, anaphylaxis has no known cause and thus the anaphylactic reaction is called idiopathic.
Anaphylaxis occurs when mast cells release large quantities of chemicals (histamines, prostaglandins and leukotrienes) that cause blood vessels to leak, bronchial tissues to swell and blood pressure to drop. Resulting conditions such as shock and unconsciousness usually resolve in most people treated with epinephrine (adrenaline) and first aid measures. In rare cases, however, death may occur.
Abnormally low blood pressure and fainting episodes are also features of mastocytosis--a disease in which people have an excessive number of mast cells. Several years ago, Dean Metcalfe, M.D., chief of the Laboratory of Allergic Diseases at NIAID, Cem Akin, M.D., Ph.D., and their NIAID colleagues decided to find out whether idiopathic anaphylaxis might have a genetic trigger related to that seen in mastocytosis. It is known that systemic mastocytosis in adults often results from a mutation in the Kit receptor found on the surface of mast cells, a discovery first made by Dr. Metcalfe's team in 1995.
The mutation causes an abnormal growth of mast cells, as is observed in bone marrow biopsies of patients with mastocytosis. So the NIAID team asked, if the Kit mutation could make mast cells grow and cause mastocytosis, and this was associated with anaphylactic reactions, could the same mutation predispose mast cells to release chemicals responsible for idiopathic anaphylaxis?
In a two-year study conducted at the NIH Clinical Center, the researchers examined 48 patients diagnosed with mastocytosis with or without associated anaphylaxis, 12 patients with idiopathic anaphylaxis, and 12 patients with neither disease. Within the group of 12 patients who had idiopathic anaphylaxis, five were found with evidence of a disorder in a line of mast cells (clonal mast cell disorder). The researchers looked for evidence of a Kit mutation in three patients by analyzing bone marrow samples, and all three samples yielded a positive result. The findings demonstrate that some patients with idiopathic anaphylaxis have an aberrant population of mast cells with mutated Kit.
"We believe the mutation may be predisposing people to idiopathic anaphylaxis," says Dr. Metcalfe. "Our findings suggest that in patients with idiopathic anaphylaxis as well as in people with severe allergies, we should look for critical genetic mutations that may change the way a mast cell reacts."
Dr. Metcalfe and his NIAID colleagues report their findings in two journals. The study that appears in an early online edition in Blood describes the presence of an abnormal mast cell population in a subset of patients with idiopathic anaphylaxis. The findings about the mechanism leading to mass cell activation by Kit and the IgE receptor responsible for allergic reactions appear online in Cellular Signalling.
According to the NIAID team, both Kit and the IgE receptor responsible for allergic reactions activate mast cells via a common interior protein of mast cells. They also found that the mutated Kit markedly elevates the activity of that protein, which results in increased cell signaling.
The scientists are now looking to see if artificial mast cells with mutated Kit behave or release chemicals in a manner different from normal mast cells, and also if they respond to inhibitors targeting Kit.
NIH/National Institute of Allergy and Infectious Diseases
Anaphylaxis occurs when mast cells release large quantities of chemicals (histamines, prostaglandins and leukotrienes) that cause blood vessels to leak, bronchial tissues to swell and blood pressure to drop. Resulting conditions such as shock and unconsciousness usually resolve in most people treated with epinephrine (adrenaline) and first aid measures. In rare cases, however, death may occur.
Abnormally low blood pressure and fainting episodes are also features of mastocytosis--a disease in which people have an excessive number of mast cells. Several years ago, Dean Metcalfe, M.D., chief of the Laboratory of Allergic Diseases at NIAID, Cem Akin, M.D., Ph.D., and their NIAID colleagues decided to find out whether idiopathic anaphylaxis might have a genetic trigger related to that seen in mastocytosis. It is known that systemic mastocytosis in adults often results from a mutation in the Kit receptor found on the surface of mast cells, a discovery first made by Dr. Metcalfe's team in 1995.
The mutation causes an abnormal growth of mast cells, as is observed in bone marrow biopsies of patients with mastocytosis. So the NIAID team asked, if the Kit mutation could make mast cells grow and cause mastocytosis, and this was associated with anaphylactic reactions, could the same mutation predispose mast cells to release chemicals responsible for idiopathic anaphylaxis?
In a two-year study conducted at the NIH Clinical Center, the researchers examined 48 patients diagnosed with mastocytosis with or without associated anaphylaxis, 12 patients with idiopathic anaphylaxis, and 12 patients with neither disease. Within the group of 12 patients who had idiopathic anaphylaxis, five were found with evidence of a disorder in a line of mast cells (clonal mast cell disorder). The researchers looked for evidence of a Kit mutation in three patients by analyzing bone marrow samples, and all three samples yielded a positive result. The findings demonstrate that some patients with idiopathic anaphylaxis have an aberrant population of mast cells with mutated Kit.
"We believe the mutation may be predisposing people to idiopathic anaphylaxis," says Dr. Metcalfe. "Our findings suggest that in patients with idiopathic anaphylaxis as well as in people with severe allergies, we should look for critical genetic mutations that may change the way a mast cell reacts."
Dr. Metcalfe and his NIAID colleagues report their findings in two journals. The study that appears in an early online edition in Blood describes the presence of an abnormal mast cell population in a subset of patients with idiopathic anaphylaxis. The findings about the mechanism leading to mass cell activation by Kit and the IgE receptor responsible for allergic reactions appear online in Cellular Signalling.
According to the NIAID team, both Kit and the IgE receptor responsible for allergic reactions activate mast cells via a common interior protein of mast cells. They also found that the mutated Kit markedly elevates the activity of that protein, which results in increased cell signaling.
The scientists are now looking to see if artificial mast cells with mutated Kit behave or release chemicals in a manner different from normal mast cells, and also if they respond to inhibitors targeting Kit.
NIH/National Institute of Allergy and Infectious Diseases
Anaphylaxis Current Events and Anaphylaxis News RSSCommon chemotherapy drug triggers fatal allergic reactions
A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.
Of Mice and Peanuts: A new mouse model for peanut allergy
Chicago researchers report the development of a new mouse model for food allergy that mimics symptoms generated during a human allergic reaction to peanuts.
Scientists developing food allergy treatment
A team of scientists from across Europe are embarking on new research to develop a treatment for food allergy.
Society's lack of food allergies impacts those afflicted with food allergies
The level of knowledge and understanding of children with food allergies varies significantly across three key groups: pediatricians and family physicians, the general public and families who have a child with food allergies. The article describing the new findings was published in the September issue of BioMed Central Pediatrics.
Higher anaphylaxis rates after HPV vaccination: CMAJ study
The estimated rate of anaphylaxis in young women after human papillomavirus (HPV) vaccination was significantly higher - 5 to 20 fold - than that identified in comparable school-based vaccination programs.
Most vaccine-allergic children can still be safely vaccinated, Hopkins experts say
With close monitoring and a few standard precautions, nearly all children with known or suspected vaccine allergies can be safely immunized, according to a team of vaccine safety experts led by the Johns Hopkins Children's Center.
Adverse reactions to antibiotics send thousands of patients to the ER
Adverse events from antibiotics cause an estimated 142,000 emergency department visits per year in the United States, according to a study published in the September 15, 2008 issue of Clinical Infectious Diseases.
Students with food allergies often not prepared
College students with food allergies aren't avoiding the foods they know they shouldn't eat. Students of all ages are not treated with potentially life-saving epinephrine as often as they should be. And instructors, roommates and friends often are not aware of what to do if a food-allergic student has a reaction.
Researchers find cause of severe allergic reaction to cancer drug
Clinicians have been perplexed by the fact that some patients given the drug cetuximab-an immune-based therapy commonly used to treat persons diagnosed with head and neck cancer, or colon cancer-have a severe and rapid adverse reaction to the drug.
Research Finds Allergic Children Exposed to Peanuts at Younger and Younger Ages Despite Recommendations To Avoid Until Age 3
The age at which children are exposed to peanuts and have an allergic response has dropped significantly over the last decade, despite recommendations that at-risk families avoid exposing children to peanuts during the first three years of life.
More Anaphylaxis Current Events and Anaphylaxis News Articles
 |
Anaphylaxis: A Practical Guide by Philip Jevon (Author) This book is a small, yet comprehensive, practical guide to the management of anaphylaxis. It will equip any healthcare worker with the essential information they need to be able to respond quickly and appropriately in the event of an anaphylactic reaction, which can be life-threatening if not diagnosed and treated effectively. * Clear, concise writing style well supported by illustrations * Detailed information on causes, features and management of anaphylaxis * Special section on paediatric aspects * Useful post-reaction information on follow-up and long-term management, including patient education * Guidance on record-keeping |
 |
(and sweet dreams) anaphylaxis (Primary Contributor) |
 |
"I'm Not Nuts": Living with Food Allergies Starring: none Directed By: Kevin J. Lindenmuth Also With: Kevin J. Lindenmuth (Producer), Kevin J. Lindenmuth (Writer) In recent years the word "allergy" has become a catch-all phrase. The term "food allergy" is misinterpreted as anything from a stomach ache to a rash, most often confused with a food intolerance. What many people do not understand is that food allergies are serious and can be life-threatening, just as an allergy to bee stings can be fatal. Through the experience of several families consisting of both children and adults with food allergies, this program clarifies the misinformation people commonly have about food allergies. Most importantly, it illustrates that food allergies are something a person can live with. Several medical professionals such as Dr. Scott Sicherer of the Jaffe Food Allergy Institute and doctors Harvey Leo and Ben Song of the Allergy & Immunology Associates of... |
|
Noise for Lovers by Anaphylaxis | |
 |
Code Blue: Complete Series (CD) by Concept Media (Author) Code Blue – two simple words that result in nurses and physicians springing into action to preserve life, restore health, relieve suffering, limit disability, and reverse clinical death. With proper education and practice, the management of a patient in cardiac, respiratory, or cardiopulmonary arrest can be optimized for the best chance of recovery. This state-of-the-art series explores the team approach to a Code Blue response through interactive scenarios. The first program is a mock code role play, and the remaining three programs are Code Blue case studies. Each of the case studies allow the viewer to click on featured icons to receive a more detailed description about the role of each member throughout the event. The final icon provides information about the treatment protocol for... |
|
Anaphylaxis Campaign Newsletter by Anaphylaxis Campaign | |
 |
Anaphylaxis (Novartis Foundation Symposia) by Novartis Foundation (Author) Anaphylaxis is an immediate-type allergic reaction involving the whole organism. It is the most life-threatening allergic condition. Although there are few exact epidemiological data regarding prevalence, estimates regarding insect sting anaphylaxis range from 1-3 0n the general population, but much higher values have been reported by some authors for food and drug-induced anaphylaxis. Anaphylaxis is the main acute killer of allergic individuals. Although anaphylaxis was discovered at the beginning of the 20th century, there are still many unresolved issues. These include non-IgE-mediated anaphylactoid reactions, non-immunologically mediated anaphylactoid (pseudo-allergic) reactions, pathophysiological events at the microcirculatory level, appropriate therapy for the acute... |
 |
Echinacea 400mg - 100 - Capsule by Olympian Labs The Native Americans first introduced us to this coneflower plant. Their first use of this plant was in the treatment of snakebites and other skin wounds. Echinacea is known for its antiviral, antibacterial and anti-inflammatory properties. Echinacea is effective against both bacterial and viral organisms that cause infection. It is most often used in the relief of the common cold. Excellent for the immune system, lymphatic system and glandular swelling related to infection. |
|
Alexander, The Elephant Who Couldn't Eat Peanuts (The Food Allergy and Anaphylaxis Network) (Animated) Also With: Food Allergy and Anaphylaxis Network (Primary Contributor), Susan Leavitt (Producer) | |
|
|
a love set to music anaphylaxis (Primary Contributor) |
| © 2009 BrightSurf.com |